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Introduction
This work describes a method to improve the therapeu-
tic effects of unmethylated CpG oligodeoxynucleotides
(ODNs) analogues which can be used to stimulate the
innate immune system. It is based upon the generation
of novel reagents that can be used to target tumors after
linkage of CpG ODNs analogues to tumor targeting
monoclonal antibodies. This approach to cancer immu-
notherapy is novel in concept and will yield important
information regarding the effectiveness of components
of innate immunity in the treatment of cancer and
related diseases and its ability to alter the tumor micro-
environment. CpG has been used exclusively as adju-
vants by injection locally at the site of interest or mixed
with a tumor vaccine. For systemic diseases such as can-
cer, however, the local administration of CpG would
limit the potential of this TLR agonist in the clinic.
Methods
In order to generate a reagent that can be used systemi-
cally, we have linked chemically active CpG motifs ana-
logues to tumor targeting antibodies (chTNT-3) such as
those that target tumor necrosis. In vitro and in vivo
studies were also performed to demonstrate that conju-
gation of CpG to chTNT-3 retained the immunostimu-
latory activity of the CpG moiety and the binding ability
of the chTNT-3 antibody.
Results
These studies validate the usefulness of this novel
approach and showed that, compared with the free
CpG, the chTNT-3/CpG immunoconjugate is able to
stimulate the immune system in vitro and reduce tumor
burden as a monotherapeutic agent in vivo. Intraperito-
neal injections of chTNT-3/CpG delayed tumor growth
and improved survival in both high and low immuno-
genic tumor models, and was not significantly different
than intratumoral injections of free CpG. Compared to
saline-treated mice, chTNT-3/CpG-treated mice had
decreased tumor volumes by as much as 70-79 % in two
diversely different tumor mouse models. Systemically
delivered free CpG and CpG conjugated to an isotype
control antibody did not reduce tumor burden or
improve survival.
Conclusions
These studies demonstrate the feasibility of antibody-
CpG immunoconjugates for targeted therapy of innate
immunity in different types of tumors and provide the
foundation for near future development and clinical
cancer immunotherapy evaluation.
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